Renaissance Capital logo

CM Life Sciences II Priced, Nasdaq: CMIIU

Second blank check company formed by Casdin Capital and Corvex Management targeting a life science business.

Industry: SPAC

Latest Trade: $13.40 0.00 (0.0%)

First Day Return: +24.9%

Return from IPO: +34.0%

Industry: SPAC

We are a newly organized blank check company. While we may pursue an initial business combination target in any industry, sector or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. Our team intends to leverage the strong life sciences knowledge base and public and private market experience of our sponsor with the goal of executing a successful business combination in the life sciences sector. Our sponsor is an affiliate of Eli Casdin, founder and Chief Investment Officer of Casdin Capital, and of Keith Meister, founder and Chief Investment Officer of Corvex Management, two leading investment firms. CM Life Sciences II has a focused acquisition strategy. We believe that the rise in both the number and quality of companies entering the genomics space today presages significant consolidation and restructuring. Our comprehensive understanding of the science, strong ties to the industry, and broad experience guiding public companies gives us a competitive advantage to help shape, and profit from, this key moment in the maturation of the industry.
more less
IPO News for CM Life Sciences II
more
IPO Data
IPO File Date 02/01/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 24.0
Deal Size ($mm) $240
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/22/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 24.0
Deal Size ($mm) $240
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2020
Employees 3